Phospho-CDKN1B (S178) Antibody

What is the biological function of CDKN1B/p27 KIP1 in cell cycle regulation?

CDKN1B encodes the cyclin-dependent kinase inhibitor p27 KIP1, which negatively regulates the Cdk2/cyclin E and Cdk2/cyclin A protein complexes. This inhibition prevents progression from the G1 to S phase of the cell cycle. During G0 and early G1, p27 KIP1 expression and stability are at their maximum. As cells progress through G1 phase, gradual degradation of p27 KIP1 occurs, which is associated with increased activity of Cdk2/cyclin E and Cdk2/cyclin A complexes that stimulate cell proliferation .

p27 KIP1 acts as an integration point for multiple signaling pathways, including mitogenic pathways (MAPK, PI3K/AKT) and anti-proliferative pathways (TGFβ/SMAD). These pathways can regulate p27 KIP1 at various levels, including transcription, translation, intracellular localization, and ubiquitin-mediated proteasomal degradation .

What is the significance of S178 phosphorylation in CDKN1B function?

S178 phosphorylation represents a critical post-translational modification site in the C-terminal region of p27 KIP1. This phosphorylation affects protein stability, localization, and function. While the search results don't provide specific details about the direct consequences of S178 phosphorylation, we can infer its importance from the development of specific antibodies targeting this modification and its relevance in cellular contexts where p27 KIP1 regulation is altered, such as in cancer cells .

The development of phospho-specific antibodies against S178 suggests this modification plays a significant role in the protein's biological function, potentially affecting p27 KIP1's ability to inhibit CDKs or interact with other binding partners .

How does p27 KIP1 function as a tumor suppressor?

p27 KIP1 acts as an atypical tumor suppressor in that it is rarely mutated in human cancers but is frequently underexpressed or mislocalized in malignancies . Unlike classic tumor suppressors that often undergo mutational inactivation, p27 KIP1 regulation is typically altered at the level of protein expression, localization, or post-translational modifications.

What are the optimal applications for Phospho-CDKN1B (S178) antibodies?

Based on the search results, Phospho-CDKN1B (S178) antibodies are validated for several applications:

The optimal application depends on your research question. Western blot is ideal for determining the presence and relative abundance of the phosphorylated protein in lysates. Immunohistochemistry provides spatial information about phospho-CDKN1B localization within tissues. ELISA offers a quantitative approach for measuring phospho-CDKN1B levels .

What controls should be included when using Phospho-CDKN1B (S178) antibodies?

To ensure reliable results with phospho-specific antibodies, include the following controls:

• Positive control: Cell lines or tissues known to express phosphorylated CDKN1B at S178, such as HL-60 cells as mentioned in the search results .

• Negative control:

  • Samples treated with phosphatase to remove phosphorylation

  • Non-phosphorylated recombinant CDKN1B protein

  • Samples from CDKN1B knockout models (when available)

• Peptide competition: Pre-incubation of the antibody with the phospho-peptide used as the immunogen should abolish specific signal .

• Total CDKN1B control: Include parallel detection of total CDKN1B (with a phosphorylation-independent antibody) to normalize phosphorylation to total protein levels.

This comprehensive control strategy helps verify antibody specificity and validates experimental findings .

How should samples be prepared to preserve CDKN1B phosphorylation?

Proper sample preparation is crucial for phosphorylation detection:

• Include phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate, β-glycerophosphate) in all lysis and extraction buffers.

• Maintain cold temperatures during processing to minimize enzymatic dephosphorylation.

• For tissue samples in IHC, rapid fixation is essential. The search results indicate successful staining in formalin-fixed, paraffin-embedded tissues, such as hepatocellular carcinoma samples .

• Store lysates with phosphatase inhibitors at -80°C and avoid repeated freeze-thaw cycles, as recommended for antibody storage .

• When working with cell cultures, consider the cell cycle stage, as p27 KIP1 expression and phosphorylation vary throughout the cell cycle, with highest levels in G0 and early G1 .

How can Phospho-CDKN1B (S178) antibodies be used to study the relationship between CDKN1B mutations and cancer?

Researchers can utilize these antibodies to investigate how CDKN1B mutations affect phosphorylation patterns and subsequent protein function:

• Comparative phosphorylation analysis: Compare S178 phosphorylation levels between wild-type and mutant CDKN1B in patient samples or model systems. For example, the search results describe a G9R-p27 KIP1 mutation that creates a new consensus sequence for basophilic kinases, causing aberrant phosphorylation at S12 . Similar mechanisms might affect S178 phosphorylation in other mutations.

• Mutation-phosphorylation correlation: Investigate whether specific CDKN1B mutations (like those identified in MEN4 patients or sporadic tumors) alter S178 phosphorylation. The search results mention several pathogenic CDKN1B mutations, including germline mutations in MEN4 patients and a 4-bp deletion in the 5'UTR that affects translation .

• Functional consequences: Determine how altered S178 phosphorylation in mutant proteins affects cyclin-CDK binding, protein stability, and subcellular localization. This can be assessed through co-immunoprecipitation, protein stability assays, and immunofluorescence using the phospho-specific antibody .

• Tumor microenvironment influence: Examine how tumor microenvironment factors influence S178 phosphorylation in wild-type versus mutant CDKN1B, potentially revealing context-dependent regulation mechanisms .

What experimental approaches can determine the kinases responsible for S178 phosphorylation?

To identify kinases that phosphorylate CDKN1B at S178:

• In silico prediction: Analyze the sequence surrounding S178 for kinase consensus motifs using bioinformatics tools.

• Kinase inhibitor screening: Treat cells with specific kinase inhibitors and assess changes in S178 phosphorylation using the Phospho-CDKN1B (S178) antibody in Western blot or ELISA formats.

• In vitro kinase assays: Perform in vitro kinase reactions with purified candidate kinases and recombinant CDKN1B, followed by detection with the phospho-specific antibody.

• Kinase overexpression/knockdown: Overexpress or knock down candidate kinases in cell models and assess the impact on S178 phosphorylation.

• Mass spectrometry validation: Confirm phosphorylation site occupancy and potential changes in phosphorylation dynamics using mass spectrometry approaches.

The search results mention "R-directed kinases" in the context of the G9R mutation , suggesting similar directed kinase analysis could be applied to S178 phosphorylation.

How does S178 phosphorylation relate to other post-translational modifications of CDKN1B?

CDKN1B undergoes multiple post-translational modifications that collectively regulate its function:

• Modification crosstalk: Investigate whether S178 phosphorylation influences or is influenced by other modifications (phosphorylation at other sites, ubiquitination, acetylation) using combinatorial antibody approaches.

• Sequential modifications: Determine if S178 phosphorylation serves as a priming event for subsequent modifications, particularly ubiquitination that targets p27 KIP1 for degradation. The search results indicate that degradation of p27 KIP1, triggered by CDK-dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for cellular transition from quiescence to the proliferative state .

• Localization effects: Examine how S178 phosphorylation affects subcellular localization compared to other modifications. The search results mention that nuclear mislocalization of p27 KIP1 can occur in tumor cells, and certain mutations (like G9R) can enhance nuclear localization through phosphorylation of other residues .

• Temporal dynamics: Map the temporal sequence of different modifications throughout the cell cycle, using synchronized cell populations and time-course experiments with the Phospho-CDKN1B (S178) antibody.

What are common causes of false negative results when using Phospho-CDKN1B (S178) antibodies?

Several factors can lead to false negative results:

• Sample preparation issues: Inadequate phosphatase inhibition during sample preparation can lead to dephosphorylation. Ensure complete protease and phosphatase inhibitor cocktails are used in all buffers .

• Antibody storage/handling: Improper storage can compromise antibody activity. Store antibodies according to manufacturer recommendations, typically at -20°C for long-term storage and 4°C for short-term use. Avoid repeated freeze-thaw cycles .

• Low expression levels: p27 KIP1 expression varies by cell type and condition. Some tissues naturally express lower levels, requiring more sensitive detection methods or sample enrichment.

• Cell cycle timing: p27 KIP1 levels change throughout the cell cycle, with highest expression in G0/G1. If cells are primarily in S or G2/M phases, detection may be challenging .

• Technical factors: Inadequate blocking, insufficient antibody concentration, or suboptimal incubation conditions can reduce signal. Follow the recommended dilutions (1:1000 for WB, 1:50-1:300 for IHC) and optimize as needed for specific experimental conditions .

How can researchers distinguish between specific and non-specific signals when using Phospho-CDKN1B (S178) antibodies?

To distinguish specific from non-specific signals:

• Peptide competition: Pre-incubate the antibody with the phosphorylated peptide used as immunogen. Specific signals should be eliminated or significantly reduced .

• Phosphatase treatment: Treat duplicate samples with lambda phosphatase. Phosphorylation-specific signals should disappear after treatment.

• Molecular weight verification: Verify that the detected band appears at the expected molecular weight of p27 KIP1 (approximately 27 kDa). The search results mention a calculated molecular weight of 22073 Da .

• Knockout/knockdown controls: When possible, include CDKN1B knockout or knockdown samples as negative controls.

• Cross-reactivity assessment: Confirm the antibody does not cross-react with other proteins. The search results note that some antibodies, like A00173S178, show no cross-reactivity with other proteins .

How should researchers interpret changes in S178 phosphorylation in disease contexts?

Interpreting phosphorylation changes requires careful consideration:

How might single-cell analysis techniques enhance our understanding of S178 phosphorylation heterogeneity in tissues?

Single-cell analysis offers new opportunities to study phospho-CDKN1B dynamics:

• Cellular heterogeneity: Single-cell techniques can reveal cell-to-cell variation in S178 phosphorylation within tissues that bulk analysis would miss. This is particularly relevant in heterogeneous tissues like tumors.

• Methodological approaches:

  • Single-cell Western blotting can detect phospho-CDKN1B in individual cells

  • Mass cytometry (CyTOF) with phospho-specific antibodies can quantify phosphorylation across thousands of cells

  • Imaging mass cytometry can provide spatial context for phosphorylation patterns within tissue architecture

• Correlation with cell state: Single-cell RNA-seq paired with phospho-protein analysis can correlate S178 phosphorylation with transcriptional cell states and cell cycle phases.

• Tumor microenvironment influence: Single-cell approaches can reveal how specific microenvironmental niches affect S178 phosphorylation in different cell populations within a tumor.

What technological advances might improve detection sensitivity and specificity for Phospho-CDKN1B (S178)?

Several technological advances could enhance phospho-CDKN1B detection:

• Next-generation antibody engineering:

  • Recombinant antibody fragments with enhanced specificity

  • Single-domain antibodies with improved tissue penetration for imaging

  • Bispecific antibodies that simultaneously recognize the phosphorylation site and another CDKN1B epitope for increased specificity

• Advanced detection systems:

  • Super-resolution microscopy techniques to visualize phospho-CDKN1B at nanoscale resolution

  • Proximity ligation assays to detect interactions between phospho-CDKN1B and binding partners

  • Digital protein quantification methods for absolute quantification of phosphorylation stoichiometry

• Biosensor development:

  • FRET-based biosensors to monitor S178 phosphorylation in living cells

  • Genetically-encoded biosensors to track phosphorylation dynamics in real-time

• Mass spectrometry improvements:

  • More sensitive targeted MS methods for phosphosite-specific quantification

  • Phosphoproteomic approaches that can measure multiple CDKN1B phosphorylation sites simultaneously

How might understanding S178 phosphorylation contribute to therapeutic approaches for CDKN1B-related disorders?

Therapeutic implications of S178 phosphorylation research include:

• Biomarker development: S178 phosphorylation could serve as a biomarker for disease progression or treatment response in conditions associated with CDKN1B dysregulation, such as multiple endocrine neoplasia syndrome type 4 (MEN4) .

• Targeted therapy approaches:

  • Development of inhibitors targeting kinases responsible for S178 phosphorylation

  • Peptide mimetics that block interactions affected by S178 phosphorylation

  • Small molecules that stabilize p27 KIP1 against degradation signaled by phosphorylation

• Personalized medicine applications:

  • Screening for CDKN1B mutations that affect S178 phosphorylation

  • Tailoring treatments based on phosphorylation status

  • Monitoring phosphorylation as a readout of treatment efficacy

• Combination therapies:

  • Identifying synergistic approaches that target both CDKN1B regulation and downstream effectors

  • Rational combinations with CDK inhibitors based on S178 phosphorylation status

The search results indicate that CDKN1B mutations can lead to various human cancers, including parathyroid adenomas, pituitary adenomas, and well-differentiated pancreatic neoplasms , suggesting potential therapeutic applications across multiple disease contexts.

What experimental design is optimal for studying dynamic changes in S178 phosphorylation during cell cycle progression?

To study phosphorylation dynamics during the cell cycle:

• Synchronization approaches:

  • Serum starvation-release protocols to synchronize cells at G0/G1

  • Thymidine block or nocodazole treatment for synchronization at specific cell cycle phases

  • Combine with flow cytometry to verify synchronization efficiency

• Time-course sampling:

  • Collect samples at regular intervals following release from synchronization

  • Perform parallel flow cytometry to correlate samples with cell cycle phases

  • Use both Western blot and immunofluorescence with Phospho-CDKN1B (S178) antibodies

• Live-cell imaging:

  • Utilize fluorescently-tagged CDKN1B constructs combined with phospho-specific antibody fragments for real-time imaging

  • Correlate with cell cycle markers (e.g., PCNA, cyclin levels)

• Quantitative analysis:

  • Apply quantitative Western blotting with internal standards

  • Use high-content imaging for single-cell quantification of phosphorylation

  • Normalize phospho-signal to total CDKN1B levels at each timepoint

The search results indicate that p27 KIP1 expression and stability are maximal in G0 and early G1, with gradual degradation during G1 phase progression , providing a framework for temporal analysis.

How should researchers design experiments to compare phosphorylation patterns between normal and diseased tissues?

For comparative analysis between normal and diseased tissues:

• Sample collection and processing:

  • Use matched normal/tumor pairs when possible

  • Process all samples simultaneously with identical protocols

  • Include phosphatase inhibitors throughout sample preparation

• Technical considerations:

  • Employ tissue microarrays for high-throughput IHC analysis

  • Use multiplex immunofluorescence to simultaneously detect phospho-CDKN1B, total CDKN1B, and cell type markers

  • Include isotype and secondary antibody controls

• Quantification approaches:

  • Use digital pathology software for objective quantification

  • Assess both signal intensity and subcellular localization

  • Analyze percentage of positive cells in addition to staining intensity

• Validation strategies:

  • Confirm IHC findings with Western blot when sufficient tissue is available

  • Consider laser capture microdissection to isolate specific cell populations

  • Validate on independent cohorts

The search results describe a case where immunohistochemistry revealed weak cytoplasmic staining of p27 KIP1 in tumor cells but strong nuclear staining in normal endothelial cells in a pancreatic lesion , illustrating the importance of comparative analysis.

What statistical approaches are most appropriate for analyzing phosphorylation changes across multiple experimental conditions?

For robust statistical analysis of phosphorylation data:

• Normalization strategies:

  • Normalize phospho-signal to total protein expression

  • Use housekeeping proteins or total protein stains as loading controls

  • Consider specialized normalization for different techniques (e.g., GAPDH for Western blot, tissue-specific markers for IHC)

• Statistical tests:

  • For two-group comparisons: t-test (parametric) or Mann-Whitney (non-parametric)

  • For multiple groups: ANOVA with appropriate post-hoc tests (Tukey, Bonferroni)

  • For paired samples: paired t-test or Wilcoxon signed-rank test

• Advanced analyses:

  • Mixed-effects models for experiments with nested designs

  • Time-series analysis for cell cycle dynamics studies

  • Correlation analyses to relate phosphorylation to other measurements

• Replication and power:

  • Perform power analysis to determine appropriate sample sizes

  • Include biological replicates (different samples) and technical replicates

  • Report effect sizes in addition to p-values

How can researchers integrate phospho-CDKN1B data with other omics datasets?

Multi-omics integration approaches:

• Phospho-proteomics integration:

  • Correlate S178 phosphorylation with global phosphoproteome changes

  • Identify co-regulated phosphorylation sites

  • Map affected signaling pathways

• Transcriptomics correlation:

  • Relate S178 phosphorylation to expression of cell cycle genes

  • Identify gene signatures associated with phosphorylation status

  • Analyze transcription factor activity potentially affected by p27 KIP1 function

• Network analysis:

  • Map S178 phosphorylation into protein-protein interaction networks

  • Perform pathway enrichment analysis of correlated molecules

  • Identify potential regulatory hubs associated with phosphorylation changes

• Computational approaches:

  • Machine learning algorithms to predict outcomes based on phosphorylation patterns

  • Causal network inference to understand regulatory relationships

  • Systems biology modeling of cell cycle control incorporating phosphorylation data

The search results indicate that p27 KIP1 integrates signals from multiple pathways , making pathway analysis particularly relevant.